Patients
Technologies
Foundry
Careers
About

For Patients
- Science for Patients
  
  Science Corporation develops advanced medical technologies to profoundly improve the human condition for the benefit of all.
  - Learn how Science helps
  - Join the patient registry
- PRIMA Visual Prosthesis
  
  BCI Vision Restoration Technology
- Restoring Vision
Technologies
- PRIMA
  
  BCI Vision Restoration Technology
  
  Biohybrid
  
  Connecting to the brain with living neurons
  
  Vessel
  
  Perfusion technology to support and extend life
  
  Ecosystem
  
  Full stack neural engineering platform
Foundry
- Foundry
  
  Leverage the advanced technologies and microfabrication capabilities developed by Science to accelerate your work from research to production.
  - Start new Foundry order
  - Commercial BCI collaborations
- MEMS Production
  MEMS process development and wafer fabrication
  
  Our capabilities
- Neural Engineering
  Build with our neural engineering toolkit
  
  Our toolkit
Careers
- The future of neural engineering isn't building itself
  
  Apply your skills to developing technologies designed to reshape the human experience for the better. We're hiring innovative thinkers committed to our mission of restoring quality of life for all.
  - Careers at Science
  - Open Positions
- Life at Science
  We invest both in and out of the office to help you focus on building a better future.
  
  Learn more
About
- Science Corporation is a clinical-stage medical technology company
  
  We work to restore quality of life to those with debilitating conditions for which there are no treatment options.
- - Latest News
    
    April 13, 2026
    
    Science's Axon Terminal Wins 2026 iF Design Award
    
    March 31, 2026
    
    Science Appoints Murat Günel, MD, as Medical Director for Brain-Computer Interfaces
    
    March 18, 2026
    
    Expert Opinion: José-Alain Sahel, M.D., on Science’s PRIMA Implant and the ‘Undreamt of’ Progress in Restoring Vision to Clinical Trial Patients
    
    March 5, 2026
    
    Science Closes $230 Million Series C to Fund Commercialization of PRIMA BCI Retinal Implant and Expansion of Clinical Trials
    
    More News